Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
Liver transplantation is currently the treatment of choice for end-stage liver cirrhosis of
different origin, as well as for a number of inborn metabolism disorders and liver tumors.
The need to perform a liver transplantation is high and amounts to 10 - 20 patients per 1
million population per year.
Experimental and clinical evidence demonstrate the harmful short and long-term effects of
ischemia-reperfusion injury (IRI) of the donor organ on the outcome of the intervention
performed. Severe manifestations of IRI of the liver transplant (LT) is one of the main
reasons for the increased length of hospitalization, the high cost of treating patients
during the post- surgery period, the development of persistent early allograft dysfunction or
loss, frequent crises of acute rejection, acute renal and multiple organ failure, and
mortality of the operated patients.
This pilot clinical study is designed to evaluate the efficacy and safety of Reparixin, which
is a new, potent and specific inhibitor of chemokine CXCL8 (Interleukin-8), as an agent to
prevent early allograft dysfunction caused by ischemia-reperfusion injury in patients
undergoing orthotopic liver transplantation.